"Designing Growth Strategies is in our DNA"
The global ophthalmic disease therapeutics market size was USD 29,504.8 million in 2018, is projected to reach USD 47,831.3 million by the end of 2026, exhibiting a CAGR of 6.1%.
Vision care has become a costly affair, taking into consideration the consistent rise in the prevalence of ophthalmic diseases across the globe coupled with the increasing cost of treatment, raising the need for cost-effective ophthalmic disease therapeutics the world over. According to the National Eye Institute, US$ 139 billion is an estimated annual economic burden of vision loss and vision disorders in the U.S. The rising burden of blindness across the globe is a key driving factor for the estimated growth in the global ophthalmic therapeutics market.
Get comprehensive study about this report by, request a free sample copy
The major pharmaceutical companies are investing significantly in the R&D of novel therapies for treating retinal disorders, which is expected to witness more innovative therapies to be approved in the coming years, driving ophthalmic disease therapeutics market growth.
Moreover, improved scenario of OTC (Over-the-counter) therapeutics in the Asian countries owing to the introduction of cost-effective ocular drugs by regional manufacturers is anticipated to boost the global ophthalmic disease therapeutics market revenue generation of ophthalmic therapeutics during the forecast period.
"Anti-inflammatory Drugs to Account for Highest Market Share by 2026"
Various drug classes in the market are anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma, and others. Out of these, anti-inflammatory drugs dominated ophthalmic disease therapeutics market share at 25.5% in 2018 and is expected to continue to emerge dominant throughout the forecast period. The rising uptake of corticosteroids in ocular diseases and improved reimbursement policies for eyecare are the major factors anticipated to boost the market of this segment during 2019-2026.
However, anti-VEGF is estimated to register the relatively highest CAGR during the forecast period. Currently, Eylea and Lucentis are the fastest-growing ant-VEGF drugs which are contributing remarkably to the expansion of this segment. The significant number of clinical trials being conducted on novel molecules for anti-VEGF activity is projected to propel the growth of the anti-VEGF segment by the end of 2026.
To get details on market share, speak to our analyst
In terms of dosage form, the market is categorized into solid, liquid, and semi-solid. The disease indications in the market are glaucoma, retinal diseases, dry eye disease, allergy & infections, and others, out of which retinal diseases was dominating in terms of revenue in 2018. Various distribution channels in the market for ophthalmic disease therapeutics are hospital pharmacy, retail pharmacy, and online pharmacy.
"Improved Distribution of Ocular Drugs to Cater to Their Rising Demand, Augments the Market Growth in Asia Pacific with the Highest CAGR"
In terms of revenue, North America accounted for a leading share in the ophthalmic disease therapeutics market in 2018 and was valued at US$ 12,037.9 Mn, which is attributable to the high prevalence of the retinal disease in the U.S. and the recent launch of potent ophthalmic disease therapeutics in the country.
Europe is considered to be the second most prominent region in terms of revenue. However, an improved distribution network of key pharmaceutical players in Asian countries coupled with the proactive government of Asian countries taking efforts to prevent & control blindness is likely to augment the growth of ophthalmic disease therapeutics in the region with maximum CAGR during the forecast period.
North America Retinal Disease Therapeutics Market, 2018
To get geographical overview of this market, request a free sample copy
"Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc. leading the Ophthalmic Disease Therapeutics market"
The current vendor landscape of the global market is highly fragmented with the emergence of small & mid-scale regional players. Eylea, by Regeneron Pharmaceuticals, Inc and Lucentis, by F. Hoffmann-La Roche AG are prominent therapies approved for major ophthalmic diseases such as macular degeneration, macular edema, and retinal vein occlusion. The products together accounted for a significant revenue of over US$ 5.0 Bn in 2018, which has strengthened their position in ophthalmic disease therapeutics industry.
In August 2018, USFDA approved Oxervate (cenegermin) for the treatment of neurotrophic keratitis, a rare disease affecting the cornea. Such green signal by regulatory authorities for the approval of novel therapies are expected to boost the number of players entering the industry in coming years. Some of the other players operating in the ophthalmic disease therapeutics market are Santen Pharmaceutical Co., Ltd., Pfizer, Inc. Allergan plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Bayer AG, and Bausch & Lomb, Inc.
According to the National Institute of Health (NIH), currently, 1.3 million Americans are blind and an estimated 2.2 million Americans are expected to be blind by year 2030. The advancements in the diagnostic technologies have improved the precision of retinal & corneal diseases diagnosis. This, coupled with introduction of disease-specific therapies, is anticipated to propel the expansion of ophthalmic disease therapeutics market size at a remarkable rate during the forecast period.
The report provides qualitative and quantitative insights on the ophthalmic disease therapeutics industry and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented on the basis of drug class, dosage form, disease indication and distribution channel.
On the basis of disease indication, the ophthalmic disease therapeutics market is classified into retinal diseases (Diabetic macular edema, macular degeneration, retinal vein occlusion, diabetic retinopathy, and others), glaucoma (Open angle glaucoma, angle closure glaucoma, and others), dry eye disease, allergy & infections, and others.
In terms of drug class, the market for ophthalmic disease therapeutics is classified into anti-inflammatory, anti-infectives, anti-VEGF, anti-glaucoma (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), and others. Various dosage forms in the market are solid, liquid, and semi-solid, while the distribution channels covered in the report are hospital pharmacy, retail pharmacy, and others.
Geographically, the market for ophthalmic disease therapeutics is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries.
To get information on various segments, share your queries with us
Along with this, the report provides elaborative analysis of the dynamics and competitive landscape in ophthalmic disease therapeutics market. Various key insights provided in the report are the prevalence of major ophthalmic disease by key countries, recent industry developments such as partnerships, mergers & acquisitions, pipeline analysis, patent landscape, reimbursement scenario by key countries, and regulatory scenario.
By Disease Indication
By Drug Class
By Dosage Form
By Distribution Channel
As per our (Fortune Business Insights) study, the global ophthalmic disease therapeutics market is predicted to reach US$ 47,831.3 million by 2026.
Consistent rise in the prevalence of ophthalmic diseases across the globe and growing investments in the R&D by key players in the development of novel therapies for treating retinal disorders are some of the key factors driving the ophthalmic disease therapeutics market.
The anti-inflammatory drug segment is the leading segment in the ophthalmic disease therapeutics market by drug class.
North America is anticipated to hold the highest market share in the ophthalmic disease therapeutics market.
Allergan plc, F. Hoffmann-La Roche AG, and Regeneron Pharmaceuticals, Inc. are some of the leading players in the ophthalmic disease therapeutics market.
The retinal diseases segment generated the highest revenue in the advanced ophthalmic disease therapeutics market by disease indication in 2018.
Asia Pacific region is expected to grow at a significant rate in the ophthalmic disease therapeutics market during the forecast period 2019-2026 attributed to the improved distribution network of key pharmaceutical players in Asian countries coupled with proactive government of Asian countries taking efforts to prevent & control blindness.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm